UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2008
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction (Commission File Number (IRS Employer
of incorporation or organization Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions ( see General Instruction A.2. below):
[_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS
(e)
SPECIAL STOCK OPTION GRANT FOR CHIEF FINANCIAL OFFICER
On June 2, 2008, the Compensation Committee of the Board of Directors approved a
stock option grant, effective as of July 1, 2008, to John B. Henneman, III, the
Company's Executive Vice President, Finance and Administration, and Chief
Financial Officer, in connection with his previously-announced appointment as
Chief Financial Officer of the Company. The stock option grant will represent
the right to acquire 50,000 shares of common stock at a per share exercise price
equal to the fair market value on the date of grant. The grant will have a
ten-year term and will vest with respect to 1/4 of the shares on December 31,
2008 and thereafter with respect to 1/36 of the remaining shares on the first
business day of each following month.
A copy of the form of stock option agreement, approved by the Compensation
Committee for use in connection with this grant, is attached as Exhibit 10.1 to
this Current Report on Form 8-K and is incorporated herein by reference into
this Item.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
10.1 Form of stock option agreement for John B. Henneman, III
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: June 6, 2008 By: /s/ Stuart M. Essig
-------------------------
Stuart M. Essig
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description
---------- -----------
10.1 Form of stock option agreement for John B. Henneman, III